Meet the 5%-Yielding Dividend Stock That Could Soar in 2026

Company Overview - Kenvue is a consumer health products company that emerged from Johnson & Johnson's former consumer healthcare business, officially becoming a stand-alone public company in 2023 [4] - The company owns a portfolio of well-known brands including Tylenol, Band-Aid, Aveeno, Neutrogena, and Listerine, focusing on self-care, skin health, beauty, and essential health [5] - Kenvue reported nearly $15.5 billion in sales and over $1 billion in profit last year, indicating its significant market presence [5] Current Challenges - Kenvue's shares have declined more than 20% this year, primarily due to concerns linking Tylenol to autism, which has negatively impacted investor sentiment [2] - The company is currently facing various challenges but has a new leadership team in place to help navigate these issues [8] Future Potential - Despite current struggles, Kenvue is expected to recover, with potential catalysts for growth identified for 2026 [3] - The company has been consistently innovating, launching over 100 new product innovations annually since 2020, which could enhance its market position [6] - Johnson & Johnson anticipated that Kenvue would achieve improved profit margins and growth as an independent entity, with more flexibility for acquisitions [7]